This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: University of Washington, University System of Maryland. Active years: 2019-2024.
Location History:
- Frederick, MD (US) (2019)
- Brunswick, MD (US) (2021 - 2024)
Company Filing History:
3 out of 2,169 
3 out of 2,025 
Years Active: 2019-2024
Title: Mark Pelletier: Innovator in Immunotherapeutics
Introduction
Mark Pelletier is a notable inventor based in Brunswick, MD (US). He has made significant contributions to the field of immunotherapy, holding a total of 3 patents. His work focuses on the development of unique lipooligosaccharide/lipid A-based mimetics that have potential applications as adjuvants in immunotherapeutic treatments.
Latest Patents
Pelletier's latest patents include innovative methods for generating lipooligosaccharide/lipid A-based mimetics. These methods utilize recombinantly engineered bacteria to produce the mimetics, incorporating specific enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases. This groundbreaking research aims to enhance the efficacy of immunotherapeutic agents.
Career Highlights
Throughout his career, Mark Pelletier has worked with esteemed institutions, including the University System of Maryland and the University of Washington. His research has contributed to advancements in immunotherapy, showcasing his commitment to improving health outcomes through innovative solutions.
Collaborations
Some of his notable coworkers include Robert K Ernst and Adeline Hajjar. Their collaborative efforts have furthered the research and development of immunotherapeutic applications.
Conclusion
Mark Pelletier's contributions to the field of immunotherapy through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.